NDAORAL-28TABLET
Approved
Nov 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OVRAL-28 is a combined oral contraceptive containing ethinyl estradiol and norgestrel, approved in 1968 as a monophasic birth control tablet. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus and endometrial environment. The product represents one of the foundational contraceptive formulations in the hormonal contraception market.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating declining team investment and likely consolidation of brand-focused roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OVRAL-28 offers limited career advancement given its LOE-approaching status and zero linked job openings. Roles focus on legacy product management, generic competition mitigation, and regulatory maintenance rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on OVRAL-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.